Any strategy must be grounded in a firm understanding of execution feasibility. Biovativ’s experience in both strategy and operations informs strategy development to formulate strategies that are feasible and align with the client’s existing infrastructure, culture and mission. We work with our clients to define and execute strategy for optimal growth and positioning in a competitive landscape across multiple therapeutic areas.

​​

Research and development has evolved to accelerate the process of drug candidate assessment with greater accuracy and precision. Biopharma and medical device companies must continually track advancements in order to effectively compete and evolve. New developments and opportunities in R&D arise out of academia or industry, requiring different approaches to optimize their utilization. Some considerations in assessing and utilizing these advances include:

• Internal assessment. In order to improve upon R&D capabilities, it is necessary to first understand the client’s current state and capabilities, in addition to goals.

• Landscape assessment. Prior to making any change in strategy or infrastructure, an understanding of the competitive landscape is required to evaluate and project R&D capabilities and pipeline development of key competitors.

• Opportunity assessment. Academia and industry opportunities are assessed to determine optimal opportunity structure (investment, partnerships, acquisition, etc.) based on stakeholder needs and requirements.

​

​

​

​

​

​

​

​

​

​

​

​

The Life Science industry is in constant need of innovative solutions in the areas of go-to-market models, commercial strategy, R&D, diagnostics, clinical data management and other business-critical areas. We help our clients navigate the landscape to find the optimal fit with respect to partnerships, mergers or acquisitions. Scientific expertise enables in-depth due diligence and assessment of the multitude of opportunities in the start-up world, academia and corporate entities to frame a comprehensive opportunity road map that fits within and complements clients' existing strategy.

​

The path of an efficacious device or drug product from the bench to patient begins with its scientific validation. Without strategic commercial planning, there are ample regulatory and commercial hurdles that may inhibit a product’s success. Additionally, different markets present different challenges. A few core components of a well-informed commercial strategy, specific to the market of interest, include:

• Competitive landscape assessment

• Market sizing and revenue forecasting

• Patient and HCP journey mapping

• Positioning and messaging

• Clinical program development

• Pricing strategy

• Value proposition

 

A strong commercial strategy includes projections of how the market is anticipated to evolve over the duration of the product lifecycle.

 

Product Launch

• A product launch shapes the trajectory of a product’s commercial performance. As any horse racing enthusiast will proclaim, a strong start right out of the gate brings favorable odds. Strong product launch strategies are predicated on strategic, tactical, and operational considerations that specifically address the unique challenges of various markets.

 

Market Access and Regulatory

• The regulatory hurdles companies in the life sciences face are constantly evolving. We help our clients develop a regulatory approach that factors in company strategy, existing infrastructure and capabilities, current and future developments, and an assessment of current solutions in the market.

​

Valuation & Forecasting

• Valuation approaches in the life sciences vary for different segments (pharmaceutical, biotechnology, medical devices). The multitude of factors that must be taken into consideration mean that there is no industry standard approach. We understand the complexity of the industry and variability dependent upon factors such as probability of success, various stages of development, therapeutic area, etc. Our scientific expertise helps inform our approach from the very beginning, ensuring the proper assumptions are made and the relevant data is utilized in building models for the most accurate risk-adjusted net present value (rNPV).